Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- FTK -2.8%, (Flotek Industries provides Q3 update - estimates revs will be approx $5.0 mln less than previously expected and incremental costs will increase by less than $1.0 mln; activity delays are largely expected to be made up for in Q4)
- DRI -2.6%, INFO -0.5%, CIFS -0.5%
Other news:
- AXON -70.6% (announces negative topline results of Intepirdine Phase 3 MINDSET Trial)
- GNCA -59.5% ( announces strategic shift to immuno-oncology/development of neoantigen cancer vaccines; corporate restructuring and exploration of strategic alternatives for GEN-003 )
- KDMN -21.1% (announces proposed public offering of common stock and warrants)
- TXMD -10.1% (prices offering of 12.4 mln shares of common stock at $5.65 per share)
- QEP -7.7% (closes Pinedale divestiture; reduced 2017 oil production guidance to midpoint of 19.75 MMbbl, natural gas production to midpoint of 167.5 Bcf and NGL production to midpoint of 5.5 MMbbl )
- SBRA -6.4% (prices offering of 16 mln shares of common stock at $21.00 per share)
- CSGP -1.8% (files mixed securities shelf offering; commenced public offering of $750.0 million of common stock)
Analyst comments:
- AFL -1.7% (downgraded to Sell from Neutral at Citigroup)
- LEA -1.3% (downgraded to Neutral from Buy at Buckingham Research)
- CAKE -1% (downgraded to Neutral from Outperform at Wedbush)
- SHAK -0.9% (downgraded to Neutral from Outperform at Wedbush)
- TCO -0.8% (downgraded to Neutral from Overweight at JP Morgan)
- INT -0.7% (downgraded to Underperform from Neutral at BofA/Merrill)
- JPM -0.5% (downgraded to Hold from Buy at Deutsche Bank)